Cellular Therapies Leading to New Treatment Options for Lymphoma Patients
A new CAR T-cell consortium, Matthew Cortese, MD, MPH, a hematologic oncologist at Roswell Park Comprehensive Cancer Center, shares that certain types of hard-to-treat lymphomas may be more receptive to immunotherapies than previously thought.
Clinical Scorecard: Cellular Therapies Leading to New Treatment Options for Lymphoma Patients
At a Glance
Category Detail
Condition Lymphoma, specifically transformed follicular lymphoma, Richter transformation, transformed marginal zone lymphoma, and B cell lymphomas Key Mechanisms Immunotherapies, CAR T-cell therapy, small molecules like venetoclax Target Population Patients with hard-to-treat lymphomas, including transformed variants Care Setting Comprehensive cancer centers and clinical trials
Key Highlights
Certain lymphomas show high receptivity to cell therapy. Venetoclax can repair the immune system in patients with chronic lymphocytic leukemia. New trials aim to enhance treatment efficacy while minimizing toxicity. Efforts are underway to mitigate neurotoxicity from cell therapies. Guideline-Based Recommendations
Diagnosis
Identify specific lymphoma subtypes for targeted therapy. Management
Utilize CAR T-cell therapy for transformed lymphomas. Consider small molecules like venetoclax for immune system repair. Implement treatment sequencing to maximize efficacy and minimize toxicity. Monitoring & Follow-up
Assess disease progression and treatment response regularly. Risks
Monitor for potential neurotoxicity associated with cell therapies. Patient & Prescribing Data
Patients with hyper-progressive lymphoma and those with transformed lymphomas recommended for hospice care.
Targeted therapies can significantly improve patient outcomes and quality of life.
Clinical Best Practices
Implement treatment sequencing to maximize efficacy and minimize toxicity. Engage in collaborative research to develop novel therapeutic approaches. Focus on achieving minimal residual disease (MRD) negative durable remissions. References
